SEC Form 25-NSE filed by Orgenesis Inc.

5/8/25 5:21:49 PM ET

$ORGS

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ORGS alert in real time by email

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

UNITED STATES

OMB APPROVAL

OMB Number:		3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:		1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

000-54329

Issuer:	Orgenesis Inc.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	20271 Goldenrod Lane
	Germantown	MARYLAND	20876
Telephone number:				480-659-6404

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Common Stock

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2025-05-08	By	Aravind Menon		Hearings Advisor
Date		Name		Title

¹	Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Get the next $ORGS alert in real time by email

SEC Form 25-NSE filed by Orgenesis Inc.

Chat with this insight

Recent Analyst Ratings for
$ORGS

$ORGS
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

New insider Malik Ariel claimed ownership of 1,200,000 shares (SEC Form 3)

SEC Form 4 filed by Director Vider Itzhak

SEC Form 4 filed by Director Adler Yaron

$ORGS
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Orgenesis Inc.

Amendment: SEC Form SC 13G/A filed by Orgenesis Inc.

SEC Form SC 13G/A filed by Orgenesis Inc. (Amendment)

$ORGS
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Large owner Safier Jacob bought $16,883 worth of shares (30,000 units at $0.56) and sold $16,259 worth of shares (30,000 units at $0.54) (SEC Form 4)

Safier Jacob bought $3,332 worth of shares (10,100 units at $0.33) (SEC Form 4)

Safier Jacob bought $213,280 worth of shares (365,140 units at $0.58) (SEC Form 4)

$ORGS
Leadership Updates

Live Leadership Updates

Cell and Gene Therapy Industry Pioneer & GMP Expert, Gerhard Bauer, Joins Orgenesis Business, Octomera, to Drive Continued Expansion of POCare Facilities and Service Support

Orgenesis Appoints Finance Veteran Elliot Maltz as its Chief Financial Officer

Proactive news headlines including Altamira Gold, AIM ImmunoTech, QC Copper and Gold and Cloud Nine Education

$ORGS
Press Releases

Fastest customizable press release news feed in the world

Orgenesis Provides Third Quarter 2024 Business Update

Orgenesis Commences Trading on OTCQX® Best Market

Orgenesis Announces Reverse Stock Split

$ORGS
SEC Filings